Novanta heads into today's Q2 print with short sellers deeply entrenched and the stock lagging a broad peer rally — a contrast that frames the debate heading into the release.
Short interest is the defining feature of the setup. At 14.3% of free float, bearish positioning is elevated and has drifted higher over the past month, up roughly 4% in shares shorted. The ORTEX short score of 73 — in the top 2% of the universe by that measure — reinforces how persistently bears have committed to this name. Borrowing costs remain low at 0.52%, and availability is comfortable at 177% relative to shares shorted, meaning there is no squeeze pressure in the lending market. Bears can add or hold positions without friction.
What makes that positioning notable today is the gap between NOVT and its peers. The stock fell 4% on Wednesday and is down 5% over the past month, even as correlated names surged. ZBRA jumped 26% on the day and nearly 30% on the week. AEVA gained 39% over the same period. and each rose more than 11%. NOVT's 11% weekly gain looks meaningful in isolation — but it came after a deeper drawdown and still leaves the stock trailing the group on a monthly basis. The divergence suggests markets have not yet extended the same re-rating to Novanta that sector peers received.
The bull and bear debate on NOVT centers on valuation versus execution. The stock trades at roughly 34x trailing earnings and nearly 20x EV/EBITDA — multiples that leave little room for disappointment. A recent analyst note available in the data (Baird, May 2026) raised the price target to $173 on an Outperform rating after the last earnings print, which itself delivered a modest 3.2% positive reaction. The mean analyst target of $175 implies about 14% upside from the current $153 — meaningful, but not wide enough to absorb much negative revision. CEO Matthijs Glastra sold approximately $1.05 million in shares on July 2, across multiple tranches near $160–$164 — above the current price — which some investors read as a signal of limited near-term conviction from the inside.
The print will test whether Novanta can deliver organic revenue growth and margin expansion credible enough to justify premium multiples, at a moment when its peer group has already rerated sharply higher without it.
See the live data behind this article on ORTEX.
Open NOVT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
